Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties

por Mortazavi, Motahareh, Eskandari, Masoomeh, Moosavi, Fatemeh, Damghani, Tahereh, Khoshneviszadeh, Mehdi, Pirhadi, Somayeh, Saso, Luciano, Edraki, Najmeh, Firuzi, Omidreza
Publicado 2023

Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met

por Damghani, Tahereh, Moosavi, Fatemeh, Khoshneviszadeh, Mehdi, Mortazavi, Motahareh, Pirhadi, Somayeh, Kayani, Zahra, Saso, Luciano, Edraki, Najmeh, Firuzi, Omidreza
Publicado 2021

Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors

por Mortazavi, Motahareh, Divar, Masoumeh, Damghani, Tahereh, Moosavi, Fatemeh, Saso, Luciano, Pirhadi, Somayeh, Khoshneviszadeh, Mehdi, Edraki, Najmeh, Firuzi, Omidreza
Publicado 2022

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

por Heppner, David, Wittlinger, Florian, Ogboo, Blessing, Shevchenko, Ekaterina, Damghani, Tahereh, Pham, Calvin, Schaeffner, Ilse, Oligny, Brandon, Chitnis, Surbhi, Beyett, Tyler, Rasch, Alexander, Buckley, Brian, Urul, Daniel, Shaurova, Tatiana, May, Earl, Schaefer, Erik, Eck, Michael, Hershberger, Pamela, Poso, Antti, Laufer, Stefan
Publicado 2023